Overview

Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Treating Relapsed/Refractory Follicular Lymphoma with Tazemetostat
Phase:
Phase 2
Details
Lead Sponsor:
Hutchison Medipharma Limited